Parenteral Drugs (India) (NSE:PDPL) EV-to-FCF: (As of Sep. 21, 2026)

Parenteral Drugs (India)  (NSE:PDPL) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Parenteral Drugs (India)'s PE Ratio (TTM) for today is calculated as:

Parenteral Drugs (India)'s share price for today is ₹2.90.
Parenteral Drugs (India)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-25.607.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Parenteral Drugs (India) EV-to-FCF Related Terms

The historical data trend for Parenteral Drugs (India)'s EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) EV-to-FCF Chart

Parenteral Drugs (India) Annual Data
	Trend	Mar13	Mar14	Mar15	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22
EV-to-FCF		Get a 7-Day Free Trial					11.78	1.76	301.19	-12,279.30	-

Parenteral Drugs (India) Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
EV-to-FCF	Get a 7-Day Free Trial															-	-	-	-	-

NSE:PDPL vs ZTS, CTLT, VTRS: EV-to-FCF Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Parenteral Drugs (India)'s EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parenteral Drugs (India) EV-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parenteral Drugs (India)'s EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Parenteral Drugs (India)'s EV-to-FCF falls into.

Parenteral Drugs (India) EV-to-FCF Calculation

Parenteral Drugs (India)'s EV-to-FCF for today is calculated as:

Parenteral Drugs (India)'s current Enterprise Value is ₹1,173.07 Mil.
Parenteral Drugs (India)'s Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parenteral Drugs (India) Business Description